Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 8-K (Current Report)
Date of Report: December 16, 2019
Reporting Period: Events occurring on December 16 and 17, 2019.
Context: The filing discloses the entry into material definitive agreements regarding financing and the restructuring of deferred expenses.
Key Financial Metrics and Transactions
This filing does not report standard periodic financial metrics such as revenue, net income, operating cash flow, or liquidity ratios. Instead, it details specific transactional financial events:
- Debt Financing: Entered into an Open End Mortgage Note for a potential loan of up to $2,000,000 in two tranches of $1,000,000 each.
- Interest Rate: 12% per annum.
- Collateral: The loan is secured by a mortgage on the company's headquarters at 1 Controls Drive, Shelton, Connecticut.
- Related Party Lender: Anil Diwan, the company's founder, Chairman, and President.
- Debt-to-Equity Swap: Converted $250,000 of deferred development fees owed to TheraCour Pharma, Inc. into 100,000 shares of Series A Convertible Preferred Stock.
Material Changes Versus Prior Period
The filing does not provide comparative financial data against prior periods. The material changes disclosed are:
- Establishment of a new secured debt facility with a related party.
- Reduction of deferred liabilities by $250,000 through the issuance of preferred equity.
- Creation of a new class of equity (Series A Convertible Preferred Stock) with specific voting and conversion rights tied to a change in control.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Governance:
- Both transactions were approved by the independent members of the Board of Directors serving as the Audit Committee.
- Dr. Anil Diwan recused himself from voting and discussions regarding these transactions due to his related-party status.
- Related Party Transactions: Significant exposure to transactions with the company's Chairman and a principal shareholder (TheraCour, owned ~90% by Dr. Diwan).
- Asset Encumbrance: The company's primary headquarters property is now mortgaged to secure the loan.
- Liquidity of New Equity: The filing explicitly states there is no market for the newly issued Series A shares.
- Conversion Restrictions: Series A shares are convertible to common stock only upon a change in control.
- The loan is structured as an "Open End" note, allowing for future tranches up to the $2 million limit.
Investor Verification Checklist
- Verify the current status of the $2,000,000 loan facility (whether the first $1,000,000 tranche has been funded).
- Confirm the total outstanding deferred development fees remaining after the $250,000 exchange.
- Review the full text of the Mortgage Deed (Exhibit 10.2) for specific covenants or default triggers.
- Assess the impact of the 12% interest rate on future cash flow requirements.
- Monitor for any future filings regarding the conversion of Series A shares or a change in control event.